Autologous CAR-T cell therapy expressing the BAFF-ligand
- Generic Name
- Autologous CAR-T cell therapy expressing the BAFF-ligand
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Substudy B: CLL Patients
Phase 1
Not yet recruiting
- Conditions
- Relapsed CLLRefractory CLLRefractory Lymphoma
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Paolo Caimi, MD
- Target Recruit Count
- 18
- Registration Number
- NCT06916767
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio, United States
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Luminary Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT06340750
- Locations
- 🇺🇸
Nationwide Children's, Columbus, Ohio, United States
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Luminary Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT05312801
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸Taussig Cancer Institute | Cleveland Clinic, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath